Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 140,482
  • Shares Outstanding, K 13,560
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,010 K
  • 36-Month Beta 4.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.35

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.88 +37.31%
on 04/02/18
11.40 -5.09%
on 04/19/18
+1.97 (+22.26%)
since 03/23/18
3-Month
7.88 +37.31%
on 04/02/18
12.98 -16.64%
on 01/30/18
-0.76 (-6.56%)
since 01/24/18
52-Week
5.42 +99.63%
on 08/14/17
22.94 -52.83%
on 04/25/17
-11.90 (-52.38%)
since 04/24/17

Most Recent Stories

More News
Innovative Cannabis Delivery Technology Boosts Discovery, Momentum in Biotech Sectors

NetworkNewsWire Editorial Coverage

CVSI : 0.6865 (-11.05%)
GWPH : 135.91 (-0.80%)
XXII : 2.05 (-8.07%)
LXRP : 1.5300 (+12.50%)
ZYNE : 10.82 (+4.44%)
LXX.CN : 1.970 (+10.67%)
Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal...

ZYNE : 10.82 (+4.44%)
Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal...

ZYNE : 10.82 (+4.44%)
Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal...

ZYNE : 10.82 (+4.44%)
Infusion of Biotechnology Into Cannabis Market Leads to Booming Growth

CannabisNewsWire Editorial Coverage

XXII : 2.05 (-8.07%)
GWPH : 135.91 (-0.80%)
INSY : 6.90 (-1.99%)
LXRP : 1.5300 (+12.50%)
ZYNE : 10.82 (+4.44%)
LXX.CN : 1.970 (+10.67%)
Worldwide Spending in the Legal Cannabis Market is Set to Grow

According to a report published by Arcview Market Research, in partnership with BDS Analytics, the worldwide consumer spending on legal cannabis is projected to reach $57 billion by 2027. North American...

MEDFF : 15.2800 (+0.81%)
KSHB : 5.0200 (-4.20%)
CANN : 4.1400 (+2.22%)
SCQBD : 0.7420 (+1.08%)
LHSIF : 0.6770 (-3.67%)
ZYNE : 10.82 (+4.44%)
LHS.CN : 0.880 (-2.22%)
Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal...

ZYNE : 10.82 (+4.44%)
Medical and Legal Cannabis Markets are Projected to Increase in Value

Data published by Energias Market Research estimates that the global medical cannabis market is expected to grow significantly from USD 8.28 billion in 2017 to USD 28.07 billion in 2024, at a CAGR of 19.1%...

CARA : 12.21 (-1.21%)
PVOTF : 0.4000 (+0.23%)
GWPH : 135.91 (-0.80%)
XXII : 2.05 (-8.07%)
ZYNE : 10.82 (+4.44%)
Zynerba Pharmaceuticals Announces Poster Presentation at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal...

ZYNE : 10.82 (+4.44%)
Legal Cannabis Sales set to Grow as California Projected to Have an Impact

According to a research by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is estimated to grow at a CAGR of 21.1% between 2017 to 2024 by reaching a value...

CANN : 4.1400 (+2.22%)
EMHTF : 3.5500 (-1.39%)
CALI.CN : 0.500 (unch)
STVFD : 0.6400 (+4.92%)
VBIO : 1.6200 (+0.62%)
ZYNE : 10.82 (+4.44%)
FNNZF : 0.3857 (+2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 11.35
1st Resistance Point 11.09
Last Price 10.82
1st Support Level 10.46
2nd Support Level 10.09

See More

52-Week High 22.94
Fibonacci 61.8% 16.25
Fibonacci 50% 14.18
Fibonacci 38.2% 12.11
Last Price 10.82
52-Week Low 5.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar